Pages
Products
GFP Adeno-Associated Virus ( AAV-KMRPG )

GFP Adeno-Associated Virus ( AAV-KMRPG )

Cat.No. :  AAV00488Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 2 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00488Z
Description This virus is a reporter AAV with capsid engineering / modification. GFP AAV-KMRPG particles contain engineered capsid derived from AAV serotype 2 (AAV2) which has insertion of peptides KMRPGAMGTTGEGTRVTRE at I588. The target cell type of this capsid engineered AAV is cardiomyoblasts.
Reporter GFP
Serotype AAV Serotype 2
Target Gene GFP
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

Adeno-associated virus (AAV) is currently at the forefront of human gene therapy clinical trials as a recombinant vector. Significant progress has been made over the past decade in elucidating the structure, biology, and tropism of different naturally occurring AAV isolates. In particular, a range of AAV capsid interactions with host receptors have been identified and characterized. These studies have allowed us to better understand the key determinants of AAV cellular recognition and entry into different hosts. Protein engineering strategies of a rational/site-directed and/or combinatorial nature can be utilized to re-engineer the different receptor footprints associated with various AAV isolates. Utilizing the knowledge provided by these advances can aid in the development of engineering strategies that better control AAV tropism, appropriately match AAV technology to specific indications, and develop personalized human gene therapy approaches. GFP adeno-associated virus (AAV-KMRPG) represents an advanced advancement in gene therapy and molecular biology, particularly useful for targeting cardiomyocytes. The capsid of this construct is derived from AAV serotype 2 (AAV2) and has been carefully engineered to include the insertion of a specific peptide sequence at position I588: KMRPGAMGTTGEGTRVTRE. This strategic insertion was carefully designed to optimize the efficiency and specificity of the viral vector to cardiomyocytes, the precursor cells that differentiate into heart cells. By specifically targeting cardiomyocytes, this engineered AAV could improve the precision and effectiveness of gene therapies aimed at regenerating damaged heart tissue or correcting genetic defects within heart cells.
Customer Q&As
How long is the AAV2 ITR sequence?

A: 145 nucleotides.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Bright visualization

We've been incredibly satisfied with the performance of GFP AAV-KMRPG in our in vitro studies. The precise modifications to the capsid ensure high targeting accuracy, and the GFP marker provides clear, bright visualization of transduced cells.

French

10/10/2021

Reliable Results

The engineered capsid ensures that the virus accurately targets cardiomyoblasts, providing consistent and reliable gene expression in our experiments.

United States

07/11/2024

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction